These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 26844723

  • 1. Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
    Su K, Lv C, Ji Z, Wang Y, Wang H, Bai Y, Liu Y.
    Am J Ther; 2018; 25(6):e609-e616. PubMed ID: 26844723
    [Abstract] [Full Text] [Related]

  • 2. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 3. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L, Chen L, Chang B, Yang L, Liu Y, Feng B.
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [Abstract] [Full Text] [Related]

  • 4. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [Abstract] [Full Text] [Related]

  • 5. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S, Liu X, Ming J, Ji Q.
    Trials; 2016 Mar 24; 17():160. PubMed ID: 27009108
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.
    Diabet Med; 2016 Apr 24; 33(4):497-505. PubMed ID: 26435365
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan 24; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

  • 8. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK, BOOST: Intensify Premix I Investigators.
    Diabetes Care; 2014 Aug 24; 37(8):2084-90. PubMed ID: 24812432
    [Abstract] [Full Text] [Related]

  • 9. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec 24; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.
    Prim Care Diabetes; 2014 Jul 24; 8(2):111-7. PubMed ID: 23953707
    [Abstract] [Full Text] [Related]

  • 11. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar 24; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 12. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.
    Exp Clin Endocrinol Diabetes; 2006 Oct 24; 114(9):527-32. PubMed ID: 17115351
    [Abstract] [Full Text] [Related]

  • 13. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov 24; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul 24; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J, Xiao W, Guo L, Li Q, Zhong L, Yang J, Yang J, Gao Y, Tian Q, Hong T.
    Acta Diabetol; 2020 Aug 24; 57(8):991-1000. PubMed ID: 32206903
    [Abstract] [Full Text] [Related]

  • 16. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R, Arbouche Z, Bachaoui M, Zinai S, Dahaoui A, Senoussaoui S, Salah-Mansour A.
    Diabetes Res Clin Pract; 2013 Aug 24; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [Abstract] [Full Text] [Related]

  • 17. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
    Chen L, Xing X, Lei M, Liu J, Shi Y, Li P, Qin G, Li C, Li Y, Wang Q, Gao T, Hu L, Wang Y, Yang W.
    Chin Med J (Engl); 2014 Aug 24; 127(2):208-12. PubMed ID: 24438605
    [Abstract] [Full Text] [Related]

  • 18. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S, Hyllested-Winge J, Gall MA, Kaneko S, Hirao K.
    J Diabetes; 2017 Mar 24; 9(3):243-247. PubMed ID: 27059529
    [Abstract] [Full Text] [Related]

  • 19. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Qureshi MS, Shaikh MZ.
    J Pak Med Assoc; 2012 Sep 24; 62(9):929-36. PubMed ID: 23139978
    [Abstract] [Full Text] [Related]

  • 20. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr 24; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.